Budesonide (Entocort EC) vs Dexamethasone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: Glucocorticoid receptor · full Crohn's Disease pipeline

Budesonide (Entocort EC)

Marketed by Padagis and partners

Approved in Crohn's Diseasesmall molecule
Weak signal

NCT01444092 · Phase 3 · completed

This was a single-arm, open-label study without randomization, blinding, or a comparator, so its findings cannot reliably distinguish Entocort’s effects from the natural course of disease or other factors. The primary safety endpoint was descriptive rather than a comparative efficacy test, with 79 of 108 treated participants reporting at least one adverse event.

Reported efficacy

Adverse Event (12 weeks): Single-arm safety study; primary outcome adverse events at 12 weeks: 79 of 108 treated children (73%) had at least one adverse event. Secondary: PCDAI fell from a mean of 19.1 at baseline by 10.0 (SD 10.1, n=105) at 8 weeks; IMPACT III rose by 7.8 (SD 13.3). (not_applicable)

Result source: NCT01444092

Dexamethasone

Ownership not recorded

Approved in Crohn's Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBudesonide (Entocort EC)Dexamethasone
Clinical remission (induction)—Not reported—Not reported
Endoscopic response (induction)—Not reported—Not reported
Clinical remission (maintenance)—Not reported—Not reported
Endoscopic response (maintenance)—Not reported—Not reported

Clinical remission (induction)

Budesonide (Entocort EC)
—Not reported
Dexamethasone
—Not reported

Endoscopic response (induction)

Budesonide (Entocort EC)
—Not reported
Dexamethasone
—Not reported

Clinical remission (maintenance)

Budesonide (Entocort EC)
—Not reported
Dexamethasone
—Not reported

Endoscopic response (maintenance)

Budesonide (Entocort EC)
—Not reported
Dexamethasone
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Budesonide (Entocort EC): registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.

Dexamethasone: no structured comparison results are available for Crohn's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Budesonide (Entocort EC)'s landscape · Dexamethasone's landscape